CRISPR Therapeutics faces challenges, but could see 90% upside potential with regulatory support.

From Yahoo Finance: 2025-04-23 08:33:00

CRISPR Therapeutics AG faces regulatory and commercial hurdles with its sickle cell disease gene therapy, Casgevy. Recent political developments may pave the way for CRISPR to secure payment and advance new treatments, with analysts predicting a 90% upside potential. However, patient hesitancy, high costs, and complex administration processes pose challenges.

CRISPR’s innovative gene therapy approach for sickle cell disease could generate up to $4 billion in annual revenue, but concerns over side effects and administration logistics have delayed revenue recognition. Despite these challenges, CRISPR remains optimistic about its prospects with more than 50 authorized treatment centers activated globally.

In addition to its sickle cell disease gene therapy, CRISPR is exploring CAR T-cell therapies and gene therapies for chronic conditions like cardiovascular disease. Recent regulatory developments, such as the Cell and Gene Therapy Access Model, support novel treatments for rare diseases, benefitting companies like CRISPR.

While CRISPR has a Moderate Buy consensus rating on Wall Street, long-term safety, efficacy, and competitive threats remain concerns. The company’s late entry into the CAR T-cell therapy market and ambitious pursuit of gene therapies for chronic conditions raise doubts. Despite potential upside in the short term, uncertainties persist for CRISPR’s long-term prospects.



Read more at Yahoo Finance: ‘Incoming Regulatory Tailwinds’ to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital